parathyroid hormone-related peptide (1-36)

Also Known As:

PTH-related protein (1-36); PTHrP (1-36)

Networked: 7 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Intercellular Signaling Peptides and Proteins: 29768
    - Parathyroid Hormone-Related Protein: 2289
      - parathyroid hormone-related peptide (1-36): 7
- Peptides: 82426
Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormones: 80400
  - Peptide Hormones: 1347
    - Parathyroid Hormone-Related Protein: 2289
      - parathyroid hormone-related peptide (1-36): 7
Biological Factors: 2472
- Intercellular Signaling Peptides and Proteins: 29768
  - Parathyroid Hormone-Related Protein: 2289
    - parathyroid hormone-related peptide (1-36): 7

Experts

1.	Aronson, Judith F: 1 article (04/2012)
2.	Bhatia, Vandanajay: 1 article (04/2012)
3.	Chao, Celia: 1 article (04/2012)
4.	Falzon, Miriam: 1 article (04/2012)
5.	Hellmich, Mark R: 1 article (04/2012)
6.	Kim, Sung O K: 1 article (04/2012)
7.	Takeuchi, Yasuhiro: 1 article (01/2011)
8.	Bosch, R J: 1 article (09/2001)
9.	Egido, J: 1 article (09/2001)
10.	Esbrit, P: 1 article (09/2001)

Related Diseases

1.	Osteoporosis 01/01/2011 - "Thus, human PTHrP (1-36) is one of the promising drugs for treatment of osteoporosis." 08/01/1998 - "This uncoupling, if it were to continue over the longer term, would predict that PTHrP-(1-36) might be a potent anabolic therapeutic agent for osteoporosis." 10/01/1996 - "In this mini-review, the theoretical basis for the exploration and development of PTHrP(1-36) as a potential therapeutic agent for osteoporosis is considered."
2.	Bone Resorption 03/01/1995 - "When tested in vitro, equivalent amounts of human PTHrp [1-36] did not produce significant bone resorption. " 01/01/2011 - "According to preclinical and some clinical data, daily subcutaneous injection of human PTHrP (1-36) could stimulate bone formation without a substantial increase in bone resorption or expected adverse events such as hypercalcemia. "
3.	Osteosarcoma (Osteogenic Sarcoma) 12/01/1996 - "Radiolabeled PTHrP-(67-86)NH2 did not bind to SqCC/Y1 cells, and PTHrP-(67-86)NH2 did not compete for binding of 125I-labeled [Tyr36]PTHrP-(1-36)NH2 to PTH/PTHrP receptors on SaOS-2 osteosarcoma cells. "
4.	Pancreatitis 04/10/2012 - "Stellate cells mediate the fibrogenic response associated with pancreatitis; PTHrP (1-36) increases procollagen I and fibronectin mRNA levels in both primary and immortalized stellate cells. "
5.	Hypercalcemia (Milk Alkali Syndrome) 01/01/2011 - "According to preclinical and some clinical data, daily subcutaneous injection of human PTHrP (1-36) could stimulate bone formation without a substantial increase in bone resorption or expected adverse events such as hypercalcemia. "

Related Drugs and Biologics

1.	Parathyroid Hormone-Related Protein
2.	Proliferating Cell Nuclear Antigen (PCNA)
3.	Messenger RNA (mRNA)
4.	Procollagen
5.	Folic Acid (Vitamin M)
6.	Fibronectins (Fibronectin)

Related Therapies and Procedures

1.	Subcutaneous Injections